Ann: Cannabinoid Extraction Facility On Target Q2 Production, page-21

It was trading on hype. Which some of us bought into (me included, not at 8c on pump'n'dump day thankfully).

There was an expectation that one decent CR would be enough to get through til when they were cash flow neutral via imminent derma revenues (possibly another to fund major advancements in pharma but SP would still have had decent support in that instance).


You're seeing the share price languishing as we are all becoming aware this will not happen. Best case scenario there will be at least one more CR than anticipated.

This is a long hold (hence why I said 2020) because we are going to be punished through diluting CRs for at least the medium term.

The directorship can continue to make advancements (and continue to receive equity for nil consideration) and maybe one day will run a company with an attractive share price that makes everyone money.